Abstract
Hyperthermia has been a modality to treat cancer for thousands of years. During this time, intensive efforts are concentrated on determining the dose of the proper treatment, but the dominantly in vitro induced cellular death does not provide enough confidence for the clinical dosing. The cell-death by heat-monotherapy applications in laboratory experiments is difficult to apply in the complementary therapies in clinical applications. The newly developed nanotechnologies offer completely new possibilities in this field as well. Modulated electro-hyperthermia (mEHT, trade-name Oncothermia) is a nanoheating technology that has selective effects on membrane rafts and on the transmembrane proteins. This effect is thermal. The thermal action is in nanoscopic range which makes the phenomenon special. Our objective is to show the dose concept on this emerging method.
Highlights
Hyperthermia, as a treatment in oncology, has a thousand-year tradition [1]
A new, emerging way is connected to various immune actions [60], which could be applied in loco-regional hyperthermia, too
Due to the linearity of the Arrhenius plot and its reverse time dimension of χ, we introduce its reciprocal value as time constant [83] as
Summary
Hyperthermia, as a treatment in oncology, has a thousand-year tradition [1]. It has tremendous fluctuations in its applications and trusts in its efficacy [2]. Other loco-regional electromagnetic heating methods work by radiative [19]-[21], or by capacitive [22]-[24], technical solutions These non-invasive electromagnetic heating solutions use a wide range of frequencies, having definitely different effects and penetration depth to the body [14]. A new, emerging way is connected to various immune actions [60], which could be applied in loco-regional hyperthermia, too This transforms the modern local hyperthermia treatment completely systemic [61] [62], reaching bystander and abscopal effects [63] [64], by production of the immune-stimulating character for both the innate and adaptive immune system [65], and turning the oncologic hyperthermia to a complex immune-therapy, attacking the far-distant metastases, named “immunotherm” therapy [66]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
